Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Annals of surgical oncology Gamboa, A. C., Zaidi, M. Y., Lee, R. M., Speegle, S. n., Switchenko, J. M., Lipscomb, J. n., Cloyd, J. M., Ahmed, A. n., Grotz, T. n., Leiting, J. n., Fournier, K. n., Lee, A. J., Dineen, S. n., Powers, B. D., Lowy, A. M., Kotha, N. V., Clarke, C. n., Gamblin, T. C., Patel, S. H., Lee, T. C., Lambert, L. n., Hendrix, R. J., Abbott, D. E., Vande Walle, K. n., Lafaro, K. n., Lee, B. n., Johnston, F. M., Greer, J. n., Russell, M. C., Staley, C. A., Maithel, S. K. 2019

Abstract

No guidelines exist for surveillance following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal and colorectal cancer. The primary objective was to define the optimal surveillance frequency after CRS/HIPEC.The U.S. HIPEC Collaborative database (2000-2017) was reviewed for patients who underwent a CCR0/1 CRS/HIPEC for appendiceal or colorectal cancer. Radiologic surveillance frequency was divided into two categories: low-frequency surveillance (LFS) at q6-12mos or high-frequency surveillance (HFS) at q2-4mos. Primary outcome was overall survival (OS).Among 975 patients, the median age was 55 year, 41% were male: 31% had non-invasive appendiceal (n?=?301), 45% invasive appendiceal (n?=?435), and 24% colorectal cancer (CRC; n?=?239). With a median follow-up time of 25 mos, the median time to recurrence was 12 mos. Despite less surveillance, LFS patients had no decrease in median OS (non-invasive appendiceal: 106 vs. 65 mos, p?

View details for DOI 10.1245/s10434-019-07526-1

View details for PubMedID 31243668